BeyondSpring to Present Corporate Overview at Jefferies London Healthcare Conference
NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) — BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ:…
NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) — BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ:…
– Received IMPD Approval to Commence Enrollment in France for Pivotal Phase 3 Study of…
FLORHAM PARK, N.J., Nov. 13, 2020 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late…
EMERYVILLE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) — Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced…
FREMONT, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) — Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company,…
LEXINGTON, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) — Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company…
TORONTO, Nov. 13, 2020 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos…
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 13, 2020 (GLOBE NEWSWIRE) — CENTOGENE (Nasdaq:…
Updated coverage decision from Novitas Solutions marks major milestone, as Company advances toward full-scale commercialization…
One-dose, oral Xofluza has been recommended for approval for the treatment of uncomplicated influenza in…
Verana Health analysis of American Academy of Ophthalmology IRIS® Registry presented in a late-breaking oral…
TORONTO, Nov. 13, 2020 (GLOBE NEWSWIRE) — Braingrid Limited (CSE: BGRD) (“Braingrid” or the “Company”),…
VASCEPA®, compared with placebo, significantly reduced primary composite first and total major adverse cardiovascular events…
Pooled data analyses from Phase III ORION-9, -10 and -11 showed that inclisiran consistently reduced…
SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology…
NEW YORK, NY, REHOVAT, ISRAEL, SINGAPORE, Nov. 13, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Todos Medical…
AUSTIN, Texas, Nov. 13, 2020 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company”…
CARB-X and Cystic Fibrosis Foundation grants provide significant additional funding to advance CF-370 for Pseudomonas…
NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) — via NetworkNewsAudio – Cybin Inc. (NEO: CYBN) announces…
– Results from analysis of three Phase 3 clinical studies showed statistically significant improvement in…